Cargando…
Timing of chemotherapy-induced neutropenia: the prognostic factor in advanced pancreatic cancer patients treated with gemcitabine / gemcitabine-based chemotherapy
Chemotherapy-induced neutropenia (CIN) was reported to be a predictor of better survival in several cancers. The objective of our study is to evaluate the relationship between the timing (onset) of CIN and prognosis. Between June 2008 and June 2015, 134 patients with confirmed advanced pancreatic ca...
Autores principales: | Chen, Yang, Shi, Yan, Yan, Huan, Wang, Yan Rong, Dai, Guang Hai |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5630440/ https://www.ncbi.nlm.nih.gov/pubmed/29029540 http://dx.doi.org/10.18632/oncotarget.16980 |
Ejemplares similares
-
Prognostic nomogram for nonresectable pancreatic cancer treated with gemcitabine-based chemotherapy
por: Hamada, T, et al.
Publicado: (2014) -
Immunobiological effects of gemcitabine and capecitabine combination chemotherapy in advanced pancreatic ductal adenocarcinoma
por: Middleton, Gary, et al.
Publicado: (2016) -
Raltitrexed–eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer
por: Reni, M, et al.
Publicado: (2006) -
Gemcitabine plus concurrent irreversible electroporation vs gemcitabine alone for locally advanced pancreatic cancer
por: Ma, Yang-Yang, et al.
Publicado: (2020) -
Gemcitabine Combined with Capecitabine Compared to Gemcitabine with or without Erlotinib as First-Line Chemotherapy in Patients with Advanced Pancreatic Cancer
por: Lim, Jae Yun, et al.
Publicado: (2015)